8-K: Dare Bioscience Nears Nasdaq Compliance with $16.5 Million Equity Raise

Dare Bioscience, Inc. announced it believes its stockholders' equity now exceeds Nasdaq's $2.5 million minimum requirement after raising approximately $16.5 million through equity sales, and intends to notify Nasdaq for a compliance determination.

Summary

• Dare Bioscience, Inc. believes its stockholders' equity is now in excess of the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1).
• This belief is based on gross proceeds of approximately $16.5 million from sales of common stock.
• The equity sales occurred under the company's at-the-market (ATM) equity offering program and equity line arrangement between March 31, 2025, and July 18, 2025.
• The company intends to notify Nasdaq of its current equity position for a determination on regaining compliance with listing requirements.
• Dare Bioscience has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024.
• After the recent share sales, approximately 12.6 million shares of common stock will be outstanding.

Sentiment

Score: 7

Explanation: The company has taken a concrete step by raising significant capital to address a critical Nasdaq listing deficiency. While there's no guarantee of Nasdaq's determination, the action itself is a strong positive indicator of management's efforts to maintain listing.

Positives

• The company believes it has achieved stockholders' equity in excess of the $2.5 million Nasdaq minimum requirement.
• Successfully raised approximately $16.5 million in gross proceeds through equity sales.
• Intends to notify Nasdaq to regain compliance, indicating proactive steps to address listing issues.

Negatives

• The company has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024.
• There is no assurance that Nasdaq will determine the company has regained compliance.
• The company still needs to meet either the $2.5 million stockholders' equity or $35.0 million market value of listed securities requirement; this filing primarily addresses the equity component.

Risks

• Nasdaq may not determine that the company has regained compliance with Nasdaq Listing Rule 5550(b).
• If Nasdaq does not determine compliance, there is a risk regarding the company's ability to raise additional capital to increase its stockholders' equity and regain compliance.
• General risks and uncertainties discussed in Item 1A of Part II of the company's quarterly report on Form 10-Q (filed May 13, 2025) and Item 1A of Part I of its annual report on Form 10-K (filed March 31, 2025).

Future Outlook

The company believes it has regained compliance with the Nasdaq stockholders' equity requirement and intends to notify Nasdaq. However, there is no assurance that Nasdaq will agree with this determination. The ability to raise additional capital is also a forward-looking consideration if compliance is not achieved.

Management Comments

• Dare Bioscience, Inc. believes its stockholders equity is in excess of the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1), and intends to notify Nasdaq of the foregoing so that Nasdaq can make a determination as to whether the Company has regained compliance with requirements for continued listing.

Industry Context

This filing primarily addresses a specific company's compliance with stock exchange listing rules, rather than broader industry trends. It reflects a common challenge for smaller or developing companies in maintaining financial metrics required for continued listing.

Stakeholder Impact

• Shareholders: Potential positive impact as the company addresses a key risk to its Nasdaq listing, which could reduce delisting concerns. However, the equity raise also implies dilution (12.6 million shares outstanding after sales).
• Nasdaq: Will receive notification and needs to make a determination on compliance.

Next Steps

• Dare Bioscience, Inc. intends to notify Nasdaq regarding its belief of regaining compliance with Nasdaq Listing Rule 5550(b)(1).
• Nasdaq will make a determination as to whether the company has regained compliance.

Key Dates

Recommendation

While the company has taken a significant step towards regaining Nasdaq compliance by raising substantial capital and believing it meets the equity requirement, the outcome is not yet certain as Nasdaq still needs to make its determination. The previous non-compliance and the ongoing uncertainty regarding the market value requirement (Nasdaq Listing Rule 5550(b)(2)) suggest a 'hold' position until Nasdaq's decision is confirmed and the company's long-term financial stability is clearer. The capital raise also implies dilution.

Keywords

Nasdaq, Listing Compliance, Stockholders Equity, ATM Offering, Equity Line, Capital Raise, 8-K, SEC Filing